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ABSTRACT
Objectives To compare the effiocy and safety of 584
(an etanercept biosimilar) wifi reference pmduct etanercept
(ETN) in patients with moderate to sqrcre rheumatoid
anhritis (M)despite mahotruate (MIX) fterapy.
Methods This is a phase lll, randomised, doubhtlind.
panllel-group, muhicente studywith a 24-ueek primary
endpoint. Paienr with moderate to severe M despite MTX
treatment rfiere randomised to receive weekf dme of
50 mg of subartaneous SB4 or ETN. lhe pdmary endpoint
was fie American College of Rheumatobgy 20% (ACR20)
response at week 24. Other efficacy endpoinB as vrall as
safety, immunogenicity and pharmacokinetic parameters
urere also measured.
Results 596 patients \,vere nndomised to either 5M
(N=299) or ETN (N=297). The ACR20 response rate at
urcek 24 in dre per-protocol set was 78.1 % for 5M and
80.3% for ElN. The 95% Cl of Se adjusted teatnrent
difference was 
-9.41%10 4.98%, $rhich is comphtely
contained within the pmdefined equivalence margin of
-159o to 15%, indicating thenpeutic equivalence
between 584 and ETN. Other efficacy endpoinB and
pharmacokin*ic endpoinr uere comparabh. The incidence
of treatment-emergent adverse events was companble
(55.2% tts 58.2%), and the incidence of antidrug antibody
development up to vrreek 24 was lo,rnr in SB4 mmpared
$/ith ETN (0.7% vs 13.1%).
Conclusions S84 was shown to be equivalent with ETN
in terms of efficacy at week 24. SB4 was nelltolerated
with a lorer immunqenic$ profile. The safety profile of
SB4 uns companble wi*r that of EIN.
Trial registration numbers NCf01 895309, Eudra0
201 2-005026-30.
INTRODUCTION
Etanercept is a recombinant human tumoru necrosis
factor (T}{F) receptor p75Fc fusion protein.
Etanerc€pt is well established and has been widely
used in clinical practice for about 15 years, with a
well-characterised pharmacological, efficacy and
safety profile.t-s Originaly licensed for use in
moderate to severe rheumatoid athritis (RA), the
thaapeutic indicacions have been stcpwise e<tended
and comprise treatment of patients with polyarticular
juvenile idiopathic arthritis, psoriatic artluitiq
anlcylosing spondylitig psoriasis and dso paediatric
psoriasis. Recendy, etanercept has been also approved
fot use in non-radiographic axial spondyloanhritis
by dre European Medicines Agenry @MA).6
A biosimilar is a biological medicinal product
that contains a version of the active substance of an
"lt"dy authorised original biological medicinalproduct (reference medicinal product). A biosimilar
demonstrates similarity to the reference medicinal
product in terms of quality characteristics, bio-
logical activity, safety and efficary based on a com-
prehensive comparability exercise.T-e
SB4 has been developed as a biosimilar to the
reference product etanercept (ETN). SB4 is pro-
duced by recombinant DNA technology in Chinese
harnser ovary mammalian cell expression sy$em.
Similar strucnual physicochemical and biological
activities of SB4 and ETN have been shown using
state-of-the-art analytical methods including pepcide
mapping TNF-cr binding assay and TNF-a neutral-
isation cell-based assay. Equivalence in the pharma-
cokinetics (PK) benreen SB4 and ETN was
demonstrated in a phase I study conducted in
healthy male subiecrs.lo The objective of rhis snrdy
was to compar€ the efficacy, safety, PK and immuno-
genicity of SB4 and ETN in patients with RA.
MEIHODS
Patients
Patients aged 18-75 years who have been diagnosed
with RA according to thc revised 1987 American
College of Rheumatology (ACR) criteria for
>6 months and J15 years prior to screening were
eligible for the snrdy. Patiens had to have active
disease defined as >5 swollen end >6 tender joints
and either erythrocyte sedimentation rate (ESR)
)28 mm/h or serum C reacrive protein {CRP)
)1.0 mg/dl despite methotrexate MTX) treatment
for )6 months (sable dose of 10--25 mg/week for
24 weela prior to sceening). Non-steroidal anti-
inflammatory drug$ and oral glucocorticoids
(equivalent co <10mg prednisolone) wete perrnit-
ted if received at a stable dose for 24 weeks prior to
randomisacion.
Major exclusion criteria consisted of previous
treaunent with any biological agents, history of
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lymphoproliferative disease, congesdve hcart failure (New York
Heart Association Class III/IV) or demyelinating disorders, diag-
nosis of'active tuberculosis (tB) and pregnancy or breasr
feeding at screening.
Mditional eligibility crircria are listed in online
supplementary appendix 1.
Stndy design
This phase III, randomised, double-blind, parallel-group snrdy
was conducted x 73 cenres across 10 countries in Europe,
Latin Amcrica and Asia. Patients were randomised in a 1:1 ratio
to receive 50 mg of either SB4 or ETN (see online
supplemenury appendix 2). Patients self-adminisered SB4 or
ETN once weekly for up to 52 weela via subcutaneous iniec-
tion. All patienrs had to take MTX {10-25 mg\reek) and folic
acid'(5-10 mg/wcek) during the snrdy. This study is currendy
ongoing and this reporr represents efficacy data up to 24 weeks
of ffearment and safety data up ro the 24-week interim reporr
daa cut-off point (21July 2014).
Shrdy endpoints
The primary endpoint was the ACR20 respons€ rate at week 24.
Other efficacy endpoinn were rhe ACRJ0 and ACR70
responses, the numeric index of the ACR r€sponse (ACR-N),
change in the disease a.tiuity score in 28 ioints (DAS2S) baed
on ESR, the area under the curve (AUC) of the ACR-N, AUC of
the change in DAS28 and the European League Againsr
Rhewnatism (ElJl-dR) response- Safery endpoints included inci-
dence ofadverse events (AEs) and serious adverse events (SAEs).
PK uralyses were performed in the PK population, which
included 4 subset of padents from pre-desigrrated sardy sites.
Key PK endpoints included serum trough concentration(C"*ed and area under the concenffadon-time curve during
thc dosing interval (AUCJ at steady state. Serum concentrarions
were determined using a validated EUSA" and PK parameters
were calculated by non-cornpartmental analyses ffinNoulin
V.5.2 or high.r, Pharsighr, Mountain View, California, USA).
Immunogenicity was measured in all padents. The immuno-
genicity endpoints were incidence of antidrug antibodies (ADAs)
and neutralising andbodies (NAbg. A single-assay approach
with SB4 tag was used to assess immunogenicity. ADfu were
measured using validated elecrrochemiluminescence immunoas-
sayg and NAbs were measured using a competitive ligand-
binding assay.
Deails on the serum mquruement and ADA deteccion assav
can be found in online supplementary appendix 3.
Statistical analpes
Sample size was determined using the hisorical data for rhe
equivalence test. The ecpected ACR20 response rare ar week 24
for both SM and ETN was oqpected to be 60% from tlre previ-
ous ETN pivotal snrdies.ll-l3 Based on the expected response
rate, the equivalence margn of 
-15Vo to 15% at week 24 .for
ACR20 resporise r:rte was calculated in line with the US Food
and Drug Administration Guidance for Industry Non-Inferiority
Clinical llials and ths Committee for Meficinal Products for
Humar Use Guideline on the Choice of rhe Non-inferiority
Margin and was also agreed with the regulatory agencies.la 1s
Given a two-sided a level of 0.05 and 809b power, the two-
sided 15% equivalence margrn required 438 patiens for the
per-protocol set (PPS). Assuming 2()t}6 loss of patients from the
PPS, the study required a minimum of 548 randomised patients.
The primary effcacy analysis for ACR2O response at week 24
was performed on the PPS in qihidl patients completed week
24 visit, received 80-I20Vo of both the expecred number of
study drug administrations and the expected sum of MTX
doses, and did not harre any maior protocol deviations affecting
the efficacy assessment, To declare the equivalence between the
two treatment groups, the 9595 CI of the adiusted trcatment dif-
ference had to be entirely contained within the equivalence
margtn of. 
-lfoh to 1596. The 9506 CI of the difference of
ACR20 response reces r /as estimared non-parametrically using
the Mantel-Haenszel weights for region while adjusting for the
baseline CFJ As a sensitivity analysis, the same analysis was
repeated for the full analysis set (FAS) with missing data x
week 24 considered as non-responses to o<plore the robusmess
of the results. Similar analyses wcre performed for ACR50 and
ACR70 responses at week 24. Other secondary endpoints are
summarised descriptively.
In addition, the expooential time-response model for ACR20
respon$e rate was used to investigate the treatment difference
during the dme course of the snrdy up to week 24.15 Details on
the time-response model are provided in online supplementary
appendix 4.
Safety and immunogenicity endpoints were analysed descrip-
tively on the safety set that included all patienrc who received at
least one dose of snrdy &ug. PK endpoinrs were summarised
descriptively on the PK population who had et least one PK
sample collected.
The analyses were performed using SAS V.9.2 software (SAS
Institure, Cary, North Carolin4 USA).
RESUTTs
Patient disposition and baseline characteristirs
Ibtient screening began in June 20J.3, and rhe 24-week evalu-
ation of the last patient occurred in April 2074. Ovetal\ 777
patienc were screened, of whom 596 patients were randomised,
A toal of 551 patients completed 24weels of trearment and
481 (80.7%) patients were included in rhe PPS (75 pariena
were excluded from the PPS due to protocol deviations, see
online zupplementary table Sl). Patients withdrew trefore week
24 mainly due to AEs (3.7o/o) and with&awal of consent {2.796)
{figure 1). The demographic and baseline disease characterisrics
were comparable benvcen treabrent gfoups (table 1),
Efficacy
The ACR20 responsc rate at week 24 in the PPS was 78.tgb for
SB4 and 80.39b for ETN. The 95oh Cl of the adjusted difference(SBLETN) in ACR20 response rate was wirhin rhe ptedefned
equivalence margn oI 
-15Vo to lSo/o in both the PPS (950/6 CI
-9.410/6 to 4.98ohl and FAS (95% Cl -5.24% to 9.t79b), ndi-
cating therapeutic equivalence betwcen SB4 and ETN (fiSure 2).
The dme-response models of SB4 and ETN up ro week 24 in the
PPS were estimated to be equivalent since dre treannent diffet-
eirce in terms of the two-norm difference was 72.7 and the 95%
CI was 4.6 to 30.0, where rhe upper limit 30.0 was less than
the pre-specified equivalence margin of 83.28 (figure 3).
The ACR50 and ACR70 response rates at week 24 in the PPS
and FAS were equivalent between SB4 and ETN. The ACR50
response rate was 46.60/o vs 42.3V8, and the ACR70 response
rate was 25.596 vs 27,6Vo in the PPS for SB4 and ETN, respcct-
ively, as shown in figure 2.
Subgroup analyses on the ACR response rates in PPS shoured
comparable renrlts tegardless of ADA $arus. The proportion of
patients who achieved ACR20 response rate emong parients
who tested negative for antibodies against ETN was 78.006 in
SB4 and 81.5% in ETN (95% Cl 
-11.12oh rc 3.9996) (sce
online supplementary table S2).
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n=181
Screening failures
Not meeting inclusion criteria (40)
Not meeting exdusion criteria (113)
Subject lost to follow-up (3)
Wthdrew consent ('18)
Other {16)
n=16
Wthdrew before
Wbek 24
Adverse event (8)
Protocol deviation (1)
lwestigator discretion (2)
Wthdrew consent (5)
Adverse event ('14)
Lack of efiicacy (3)
Inv€stigator discr€tion (1)
Withdrew consent (11)
Figure 1 Summary of patient disposition. A total of 777 patients urere screened and 181 patients were excluded mainly due to not meeting the
exdusion criteria. Multiple streening failure reasons were possible. All patients randomised were included in the full analpis set and the safdry set
Of the 551 patients wfio completed 24 weeks o{ treatment, 481 patients rarcre included in the perarotocol set ETN, etanercept.
Tahle I Baseline demoqnphic and disease characteristics
SBf 50 mg EIN 50 mg
il=297 l{*596
Aqq {years},,mean {SD}
Age gru4. n (%)
<55 years
>65 years
Gendel n (ui)
Male ' ,
kmale
Race n (%)
MU:
Amedcan hrdian or Ahskan Naive
I'n0ther
raqt tof, mean 6Bi
Heistrt km), mean 6D)
BMt {kgrm'?}, npan (50)
llsease duration {years), mean (SD}
Durarion of MIX use (months), mean (SD)
MTX dose (mg/uaek), meqn {SD}
Sumllerr ioint count {O+O). mean (5D}
Tender ioint (ount ({F68}, mean tSD)
HA+01 (0-3), mean {SD)
Pttpician global assessment VAS (f100). mean (5D)
Subiea qlobal assessment VAS (F'|00), mean (SD)
Subiect pain asesgnent VAS {r.l00), mean (SD)
0A528 {ESR).:mean 60) ,
C reactivr pmtein (mg/dt), mean {5D}
Erythrocyte sedimentation nte (mmJh), mean (5D)
Hheumatoid factor positive, n {o/o)
92.1 (11.77:,
(84.6)
tl54)
(15.7)
(833)
te3.3)
(1.7)
(3.1
(1J)
(15.s3)
(8,78)
6,sl)
{420}
Fe.87)
{4.52)
t.4s)
{11.e0)
{05s3)
fi5:s}}
(rq.e7)
QozzJ
{030
0.00)
t22.10)
oe3)
(r1.53)
t8&z)
tr 1.8)
(14.8)
{8s.2)
{el.e)
Q.4l
fi:a)
{1.3}
(14.53)
t8.5s)
(s.30)
{4.41)
l&.771
(460)
fr.30)
(12.64)
(0550)
(r1.76)
(17.70l'
t!e.?2)
($.88)
tl.60)
82.62l,
0?.CI
5t.s
515
81
94
502
552
l2
24
8
71,8
lu.4
26.5
6.1
47.7
15.5
15;2
27.5
1.50
$2.7
62A
62,1
6.5
lt
46F
458
(1 1.67)
(86.4).
(r3.6)
0s.8)
{84.2)
{e2.6)
{2.0)
{4,0)
fl.3)
(15.3o)
(8.65)
(s.4r)
(4.30)
(40.29)
{4.56)
o.3e)
(r2.25)
(0.s56)
(14p21
08.35)(ts.l|t
{0,s9}
(r.81)
p2.34)
p8.5)
51.5
262
35
253
46
50
249
279
)
tl
4
72.5
154.4
25.8
6.0
4n.2
15.6
15.4
23.5
1.49.
62.2
61,7
6,|.8
5.5
1.5
46.5
237
44
253
273
7
t3
I
71.0
164.4
25J
6.2
47.1
i 5.5
t5.0
23.6
1.50
532
63.0
623
6.5
1.3
46A
t3l
8Ml, body mass indef DA98, disease activity score in 28 ioints; ETN, tefaence ptoduct etaner(ept EsR, efydrforyte s€dm$tation lae; HAeDl, Heahh tusessmem
Questionnairc{risabifig hrde4 MTX methouerae; VA5, visual analogue scale.
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Figure 2 American Colhge of Rhemmbsy (ACR) reryonse ntes at
u€ek 24. The adiusted ueafinent difference and iE 95% Cl wre analped
wi$ baseline C reactirn pmtein as a covariate and suatffied S rcgion.
{A} ACR 20% (ACR20} rcsponse rates of SM and €tanercept (ETN) in the
perarutocol set and full analpis set (B) ACR50 nsponse rates of 584 and
FIN in the pramtocol set and full analpis set. {O Affi70 rcsponse r*es
of 584 and FIN in ttrc perprotocol set and full analsis set *0ne patient
from ttre 584 Eanp was excluded from fre FAS due to mlsing efficcy
data at baseline.
The mean improvement in DAS28 from baseline was 2.6 and
2.5 at week 24 in SB4 and ETN, respectively (95% CI 
-0.14 to
0,28) (figure 4A). The proportion of padens achieving good or
moderate EULAR response {figure 4B), low-disease activrty
score or remission (figure 4C) af week 24 according to DAS28
were similar between SM and ETN. The ACR-N et week 24
was 45.0% in SB4 and 43.7Vo in ETN. The AUC of ACR-N up
to week 24 (58?;2.2 vs 5525.0) and rhe AUC of change in
DAS28 from baseline up to week 24 (358.3 vs 343.5) were
comparable between SB4 and ETN.
Safeq
Overall, 165 (55.2W patients in SB4 and 173 (58.2Vo) patients
in ETN reponed at least one treatment-emergent adverse evenr
CIEAE). Frequendy ocorrring TEAEs by preferred term are
shonrn in table 2, and the most frequently reported TEAE were
upper respiratory trirct infection Q.0%j nd danine aminotrans-
ferase increased (5.0%) in the SB4 and injection site erythema
(17.796|, upper respiratory tract infection (5.1%) and nasophar-
yngitis (5.1%) in ETN. Most of the TEAEs were mild to moder-
ate in severity, and TEAEs considered related to the study drug
were reponed rrr 83 (27.8%) and 105 (35.7Vo) pauenc for SB4
and ETN, respectively. Serious TEAEs were reported in 13
patients cach in SB4 and ETN and 34 pariena discontinued
lreatnent due to TEAE (15 (5.0%) patients vs 19 (6.4%)
patients).
A total of 25 patients (13 patietrts for SB4 and t2 parients for
ETN) were diagnosed at screening with latent TB but enrered
the study after completing at lcast 30 days of treatment for
latent TB and while receiving reafinenr. None of these parients
or any other patients developed active TB during the snrdy.
Clther serious infections were reported in one (0.3%) patient in
SB4 and fow (l.3Vol patients in ETN. Malignancies were
reported in threc (1.0%) paticnts in SB4 (basal cell carcinoma,
breast cancer and lung cancer meashtic) and in one (0.3Vo)
patient in ETN (invasive ductal b,reast carcinoma).
Injection site reacdons (ISRs), counted by the highJevel
group term of administration site reactiong occurred in fewcr
patients in SB4 compared with ETN. There were 22 ISRs
reported in ll (3.7%\ patients vs 155 ISRs reporrcd in 5L
(17.2o/o) patients in SB4 and ETN, respectively (p<0.001).
Most of the ISRs occurred early (berween weeks 2 and 8) and
were mild in severity. The incidence of ISR for SB4 and ETN
wete 3.7Vo vs 17.1o/o in ADA-positive patients and 0.0V0 vs
77.95/o in ADA-negative patients, respectively (see online supple-
mentary table S3).
One death was reporred in the SB4 creatmenr group due to
cardiorespiratory failure, which was not considered related to
the snrdy drug.
Pharmacokinetics
PK andyses were performed on79 patients (41 padena in SB4
and 38 patients in ETN).
C6r4, were comparable at each cime point berween SB4
(rangne hom 2.4\9 to 2.885 pg/ml in weels 2-24) and ETN
(ranerng fuom 2.066 to 2.635 WfalJ- n weeks ?-24) (see online
supplementary figure S2). The AUC" at week 8 was 675.4 vs
520.9 pg tr/ml and the imer-subiect variability (CV%) was
i7 .79fr vs 50.1% in SB4 and ETN, respectively (see onlinc sup-
plernentary figure S3).
lmmunogmicity
The incidence of ADAwas significandy lower in SB4 compared
with ETN. Two (0.7Vo) patients in SB4 and 39 (13.f%) patiene
in ETN tested positive at least once up to week 24 (p<0.001),
and only one samplc from the ETN group had neutralising.cap-
acity. The ADAs appeared early (benvcen weela 2 and 8), and
most of the ADAs disappeared after week 12 (see online
supplementary appendix 9).
DtscusstoN
In this randomiscd double-blind, parallel-group, muhiccntre
study, the effrcacy, safety and immunogeniciry of SB4 were com-
pared with those of ETN in patients with moderate to severe
Emery P, er aL Ann Rheum Dis 201 5;0:1-7. doi:10.1 l3Slanmheumdis-Z0li207588
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RA despite MTX trearment. Equivalence of effcacy bcnveen
SB4 and ETN was demonsnated and the safety of SB4 was gen-
erally comparable to ETN.
The primary endpoint at week 24 was met: the 95Vo Cl oI
the adjusted Eeatment difference between SB4 and ETN in
ACR20 r€sponsc nrte wes within the predefined equivdence
margtn of 
-tSoh to 15%. The ACR20 responses observed in
this study (73.8oh for SB4 and 7l.7oh for ETN in FAS) were
within the range of ACR20 response rates reporred in pivoal
studies with ETN (49-86%)4 11-13 17-1e but slightly higher than
what was assumed (50%). Since acdve rrearnent is used in borh
groups, biosimilar studics terrd ro show higher ACR20 response
retes2wzz compared wirh pivotal connolled srufies.
As the primary e{fcacy assessrnent (ACR20 response at week 24)
was evaluated at a time poinr in the therapeutic plateau, various
effrcrcy cndpoins and smtistical medrods were applied to detect
any non*quivdence in effiacy and to support the robusmes of
the primary efficacy analpis. The ACR20 response rare, ACR-N
and DAS28 were measured at several different time points early in
the ueatment period The time-response curves of SB4 and ETN
12
Time (ureek)
c
24812.t624
"Iirne (w€eks)
figure 3 Estim*ed time-response curues of Amedcan College of
Rheumatology 200i (ACR20) response nte up to week 24 in rhe
per-protocol set. For details of the estimaiwr process, please rufer to
the main texl. ETN, etanercept
Figure 4 Changes arer time in tre
disease astivity scon in 28 joints
(DA528) and European League Against
Rheumatism (EULAR) responses at
t\€ek 24 in the full analpis set (A)
Change in DA528 up to rcek 24.'(B)
EULAR response based on DA528. (C)
Proportion of patients achiwing
lovrFdisease aaivity score ([DAS)
defined as DA528 <32 and remission
defined as 0A528 <2.6. ffN.
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up to week 24 showing rhe ACR20 response orrer time were esti-
mated to be equivaleng and theAUC of ACR-N up toweek24 and
AUC of the change in DAS28 (ESR) from baseline up to week 24
were comparable between SB4 and ETN, indicating that the effi-
cacy of SB4 over time was similar to ETN.
Overall, the safety profile of SB4 was comparable with that of
ETN and was similar to those observed in the pivotal trials with
ETN, There were no cases of active TB and only one padent in
SB4 and four patients in ETN reported serious infection, which
is lower than 5.3026 shown in ETN product informadon.6
Malignancies wete reported in three (1.0%) parients in SB4 and
one (0.3%) pauent in ETN. The incidence of malignanry
observed in this study is similar to the previously conducted
studies.ll E 2a Interestingh ISfu were reported in fewer
patients from SB4 compared with ETN (3.7Vo vs 17.20/o).The
proportion of patients who experienced at least one ISR from
ETN goup in this smdy (I7.29b, is in line with recendy con-
ducted studies with 50 mg once weekly ETN,r3 and most ISRs
occurred in the first month, which is in accordance with the ref-
erence produfi label.6 26 Although it is unclear why the inci-
dence of ISR rvas lower in SB4 compared with ETN, the
difference in drug product formulation and container closure
system may have conribured to the lower ISR. The only differ-
ence in drug composition between SB4 and ETN is the absence
of L-arginine in SB4. It has not been shown that L-arginine is
associated with increased risk of ISR; however, we cannot pre-
clude the sole difference in formulation (abaence of L-arginine)
as the cause of ISR. In addition, nanEel rubber latex known to
cause hypersensitiviry reactions has not been used in the needle
shield of SB4. There appears to be no correlacion between ISR
and ADA development, which is consistent with previously con-
ducted snrdies.T
In this studg Qrougn and steady stare PK was investigated in a
subset of population to provide supporting evidence to the
phase I comparative PK snrdy in healthy subiecrs, which demon-
strated similar PK behaviour. In the phase III study, rhe C6.,o*1
values were comparable berween SB4 and ETN at each time
point and AUC" at steady state was telatively higher in SB4 com-
pared with ETN; however, the numericd difference is likely due
to an inherent high iner-subiect variability (37.7oh vs 50.1026).
The incidence of ADA shorrn in the ETN group of this study
(13.1%) is seemingly higher compared with what has been
reported in the previous studies.6 In this snrdy, the assay used to
dececc immunogcnicity wa$ more sensitive and immunogenicity
was measured more ftequently; mosr of the ADAs were detecred
at week 4 in this study while immunogenicity was not measured
at these tinre poinrs in the previous studies and could have
resulted in higher overall incidence of ADA in rhis study.l'l a5 27
The characteristics of andbodies detected in this study were gen-
erally nansient and non-neutralising which is in accordance
wfth those established with ETN in previous srudies.5 5 Sinc.
SB4 tagged single-assay approach was used to detect immuno-
genicity, the assay method does not seem ro have caused the
lower incidence of ADA obscrved in SB4 compared with ETN
(0.77o vs l3.lo/o). There are product-specific facors known to
affect immunogenicity, such as product origin (foreign or
human), product aggregares, impurhieg container closure
systeml28-'ll however, factors contributing to lower immunogen-
icity of SM are to be furthcr investigated. Yet, according to the
EMA guideline on biosimilarsT the lower immunogeniciry of
SB4 does not preclude classificarion as biosimilar since clinical
etficacy of SB4 and ETN were equivalent in patients with
ADA-negative results and no apparent correlation besrveen ADA
and dinical response or safety was observed.T Ls 32 33
To date, this is the 6rst global, mulcicenre study comparing
an ETN biosimilar to reference product ETN. Confirmed
equivalence of SB4 and ETN in this snrdy may provide an alter-
nadve treatfirent option for RA and allow better access to biolo-
gics for patients.
coNcLustoNs
SB4 was shovrrn to be equivalent in terms of clinical efficacy
when compared with ETN. SB4 was well tolerated wirh a com-
parable safery profile to ETN.
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